TFA
KNTE

Toth Financial Advisory’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Toth Financial Advisory’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22
Closed – – 819
2022
Q3 		$0 Buy
+22
New +$288 ﹤0.01% 821

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Toth Financial Advisory's KNTE Position: Q4 2022 in Review

Toth Financial Advisory sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 22 shares.

Toth Financial Advisory first reported a position in KNTE in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Toth Financial Advisory reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Toth Financial Advisory sold 22 Kinnate Biopharma Inc. Common Stock shares in Q4 2022.
  • Toth Financial Advisory first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Toth Financial Advisory's Kinnate Biopharma Inc. Common Stock position peaked at $0 in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Toth Financial Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.